European patents for Generex

September 2007
European Pharmaceutical Executive;Sep2007, p9
The article reports that the European Patent Office has granted the fourth European patent of Generex Biotechnology Corp. entitled "Proteinic Drug Delivery System Using Membrane Mimetics." The patent includes formulation and process claims for liposome pharmaceutical formulation, which was validated in nine European countries. Generex's flagship product, oral insulin for Type-1 and Type-2 diabetes, is now available for sale in Ecuador.


Related Articles

  • Rapid- and slow-acting insulins help control diabetes. Zablocki, Elaine // Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p46 

    The article enlightens about the availability of two rapid-acting insulins with a more rapid onset and shorter duration of action than regular insulin to contain blood sugar levels in people with diabetes, whose population is increasing at an alarming rate in the United States. Byetta is a new...

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • Europe narrows patent gap with America. Schiermeier, Quirin // Nature;6/27/1996, Vol. 381 Issue 6585, p721 

    Reports on the 8.1 increase of patent applications by European countries to the European Patent Office compared to a 5.3 percent increase in American applications. Accelerating patent trends in Europe; Proposal for the reduction of patent application costs.

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • GENEREX REPORTS A NET LOSS OF $2.6 MILLION FOR THIRD QTR.  // Biotech Financial Reports;Aug2003, p1 

    Generex Biotechnology Corp. of Toronto, Ontario, a leader in the area of buccal drug delivery, has announced financial results for its third fiscal quarter ended April 30, 2003. The company reported a net loss for the quarter ended April 30, 2003 of $2.6 million, compared to a net loss of $3.2...

  • Generex Receives Patent for Buccal Delivery of Insulin.  // BioPharm International;Dec2006, Vol. 19 Issue 12, p12 

    The article reports on the acquisition of an Australian patent by Generex Biotechnology Corp. for its micellar system that delivers macromolecules through buccal lining. Excipients will form a spherical micelle of surfactant molecules which will shield the protein from digestion by buccal...

  • Opsona Therapeutics announces issuance of new patent from European Patent Office on development and use of an antibody directed against Toll-like Receptor TLR-2.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article informs that the European Patent Office has issued the EP Patent 1,664,118 which covers Opsona Therapeutics Ltd.'s antibody directed against Toll-like Receptor-2 (TLR-2). TLR-2 plays an important role in the induction and progression of a number of inflammatory conditions including...

  • Firms Writing Prescriptions to Distant Shores. P., Shankar // njbiz;2/9/2009, Vol. 22 Issue 6, p15 

    The article focuses on pharmaceutical companies that are exploring overseas markets. Japanese drug company Daiichi Sankyo in January 2009 set up operations in Puerto Rico. Canada-based Generex Biotechnology Corp. has secured regulatory approval for its drugs in Ecuador, India and Lebanon....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics